Altshuler Shaham Ltd acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 203,740 shares of the company’s stock, valued at approximately $801,000.
A number of other hedge funds have also recently bought and sold shares of VYGR. AQR Capital Management LLC boosted its holdings in Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Voyager Therapeutics in the 1st quarter worth about $218,000. Acadian Asset Management LLC boosted its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after buying an additional 206,758 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after buying an additional 11,929 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after buying an additional 6,748 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.
Voyager Therapeutics Stock Up 2.5%
Shares of VYGR opened at $3.62 on Thursday. The business’s 50-day moving average price is $3.81 and its 200-day moving average price is $3.93. Voyager Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $5.55. The stock has a market cap of $218.72 million, a PE ratio of -1.84 and a beta of 1.25.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on VYGR. Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Wednesday, April 15th. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. Finally, Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.50.
View Our Latest Research Report on VYGR
Insider Buying and Selling at Voyager Therapeutics
In related news, CEO Alfred Sandrock sold 11,511 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the transaction, the chief executive officer directly owned 472,549 shares in the company, valued at approximately $1,828,764.63. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 12.70% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.
Featured Articles
- Five stocks we like better than Voyager Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report).
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
